SEC Comment Letter 0000000000-23-014145 to Cyclerion Therapeutics, Inc. (CYCN)

Cyclerion Therapeutics, Inc.
Date: Dec. 28, 2023 · CIK: 0001755237 · Accession: 0000000000-23-014145

View on Edgar

AI Filing Summary & Sentiment

File numbers found in text: 001-38787

Date

December 28, 2023

Author

Not clearly detected

Form

UPLOAD

Company

Cyclerion Therapeutics, Inc.

Letter

United States securities and exchange commission logo December 28, 2023 Peter M. Hecht Chief Executive Officer Cyclerion Therapeutics, Inc. 245 First Street, 18 Floor Cambridge , Massachusetts Re:Cyclerion Therapeutics, Inc. Form 10-K for the Fiscal Year Ended December 31, 2022 Filed March 22, 2023 File No. 001-38787 Dear Peter M. Hecht: We have completed our review of your filings. We remind you that the company and its management are responsible for the accuracy and adequacy of their disclosures, notwithstanding any review, comments, action or absence of action by the staff. Sincerely, Division of Corporation Finance Office of Life Sciences

Show Raw Text

United States securities and exchange commission logo
December 28, 2023
Peter M. Hecht
Chief Executive Officer
Cyclerion Therapeutics, Inc.
245 First Street, 18 Floor
Cambridge , Massachusetts
Re:Cyclerion Therapeutics, Inc.
Form 10-K for the Fiscal Year Ended December 31, 2022
Filed March 22, 2023
File No. 001-38787
Dear Peter M. Hecht:
            We have completed our review of your filings. We remind you that the company and its
management are responsible for the accuracy and adequacy of their disclosures, notwithstanding
any review, comments, action or absence of action by the staff.
Sincerely,
Division of Corporation Finance
Office of Life Sciences

SecProbe.io